Clinical trial
A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior…
NCT00412958 · ThromboGenics, Industry · Completed
Key facts
| NCT number | NCT00412958 |
|---|---|
| Title | A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III) |
| Official title | A Multicenter, Randomized, Placebo-Controlled, Double-Masked, Parallel Group, Dose-Ranging Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial |
| Lead sponsor | ThromboGenics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Vitrectomy |
| Intervention type | Drug |
| Interventions | Ocriplasmin 25µg, Ocriplasmin 75µg, Ocriplasmin 125µg, Placebo |
| Enrollment | 125 |
| Start date | Dec 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Dec 19, 2006 |
| Last update posted | Dec 17, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: